Fewer than 10% of people that would benefit from obesity jabs such as Wegovy can access them, warns the global health agency as it issues its first guidance on the medications.
Considering in excess of 1,000,000,000 individuals worldwide now obese, it is advocating for broader and more equitable availability to GLP-1 medication.
According to forecasts, in excess of 2,000,000,000 could be obese by 2030 unless action is taken.
"The new guidance acknowledges that obesity is a lifelong illness that can be managed with thorough and lifelong support," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and distribution challenges are key barriers to widespread availability to the jabs that can assist patients in reducing substantial weight, notes the body.
GLP-1 Therapy Scarcity
Despite the present most optimistic case, the production of GLP-1 therapies would only suffice for about 100 million people – less than 10% of those who need them, according to the health organization.
The advice urges governments and firms to increase access, via approaches like licensing agreements.
The intellectual property rights on a key compound – the primary ingredient of the drug Wegovy – is set to lapse in several nations in 2026.
How Obesity Drugs Work
These medications replicate a biological compound to reduce digestion speed, reduce hunger and increase satiety so users reduce food intake.
Patients typically see weight reduction within a few weeks of beginning the regular doses.
Evidence suggests users may regain a significant portion after a year of discontinuing the medication, when their normal appetite return.
To be carrying excess weight elevates your risk for experiencing medical conditions, including type 2 diabetes, cardiovascular issues, stroke, and specific cancers.
Excess weight concerns individuals in all nations and was linked to millions of fatalities worldwide in 2024, according to the WHO.
